Of the four main types of Leukemia, Acute Myeloid Leukemia (AML) diagnoses make up nearly one-third of new leukemia cases and is most likely to occur in adults. Although common cancer treatment methods are used for AML patients, only about half go into remission after chemotherapy treatments. Factors such as age and overall health contribute to these remission rates. Researchers at top life science institutions around the world continually study AML to gain better understandings of the biology of this cancer that can lead to new and more effect treatment methods. (Image courtesy Wikimedia Commons)
Read MoreTags: CA, Leukemia, new research funding, cancer research, San Diego, SDVS, UCSD, Biotechnology Vendor Showcase, cancer research funding, 2018, AML Research, Acute Myeloid Leukemia